259 related articles for article (PubMed ID: 19204654)
21. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
[TBL] [Abstract][Full Text] [Related]
22. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
23. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
Kornstein SG; Li D; Mao Y; Larsson S; Andersen HF; Papakostas GI
CNS Spectr; 2009 Jun; 14(6):326-33. PubMed ID: 19668123
[TBL] [Abstract][Full Text] [Related]
24. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
[TBL] [Abstract][Full Text] [Related]
25. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
[TBL] [Abstract][Full Text] [Related]
26. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
[TBL] [Abstract][Full Text] [Related]
27. Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants.
Nelson JC; Zhang Q; Kelin K; Eriksson E; Deberdt W; Berk M
Curr Med Res Opin; 2013 Jul; 29(7):827-33. PubMed ID: 23581532
[TBL] [Abstract][Full Text] [Related]
28. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
29. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
[TBL] [Abstract][Full Text] [Related]
30. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
31. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L
J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
[TBL] [Abstract][Full Text] [Related]
32. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
33. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
Cookson J; Gilaberte I; Desaiah D; Kajdasz DK
Int Clin Psychopharmacol; 2006 Sep; 21(5):267-73. PubMed ID: 16877897
[TBL] [Abstract][Full Text] [Related]
34. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
[TBL] [Abstract][Full Text] [Related]
35. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
Romera I; Pérez V; Menchón JM; Schacht A; Papen R; Neuhauser D; Abbar M; Picard H; Gilaberte I
J Affect Disord; 2012 Dec; 143(1-3):47-55. PubMed ID: 22858211
[TBL] [Abstract][Full Text] [Related]
36. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
37. Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.
Dunlop BW; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
J Affect Disord; 2018 Mar; 229():111-119. PubMed ID: 29306690
[TBL] [Abstract][Full Text] [Related]
38. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
39. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials.
Harada E; Kato M; Fujikoshi S; Wohlreich MM; Berggren L; Tokuoka H
Int J Clin Pract; 2015 Oct; 69(10):1139-48. PubMed ID: 25980552
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
